The estimated Net Worth of Burkhard Blank is at least $1.81 millió dollars as of 1 August 2018. Burkhard Blank owns over 6,250 units of Acorda Therapeutics Inc stock worth over $22,704 and over the last 8 years he sold ACOR stock worth over $582,307. In addition, he makes $1,202,610 as Chief Medical Officer and Head of R&D at Acorda Therapeutics Inc.
Sign up
Burkhard Blank ACOR stock SEC Form 4 insiders trading
Burkhard has made over 5 trades of the Acorda Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 6,250 units of ACOR stock worth $103,125 on 1 August 2018.
The largest trade he's ever made was exercising 25,000 units of Acorda Therapeutics Inc stock on 18 May 2018 worth over $412,500. On average, Burkhard trades about 3,016 units every 32 days since 2016. As of 1 August 2018 he still owns at least 34,400 units of Acorda Therapeutics Inc stock.
You can see the complete history of Burkhard Blank stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Burkhard Blank biography
Dr. Burkhard Blank M.D. is Chief Medical Officer and Head of R&D of the Company. Dr. Blank has been our Chief Medical Officer since July 2016, and in March 2019 he was also appointed as our Head of R&D. Prior to that, from January 2016 to June 2016, Dr. Blank was engaged by the Company to assume chief medical officer responsibilities on an interim basis. Dr. Blank has more than 28 years of experience in the pharmaceutical industry. Prior to working for the Company, from June 2014 to June 2016, Dr. Blank was the Chief Medical Officer of Herantis Pharma. From June 2013 to May 2014 he was the Chief Executive Officer of Laurantis Pharma and from June 2012 to May 2013 Dr. Blank acted as a consulting chief medical officer. Prior thereto, from October 2010 to June 2012, Dr. Blank served as a consulting chief medical officer for Mersana Therapeutics. Dr. Blank previously consulted as chief medical officer and served in various medical leadership roles for several biopharmaceutical companies, including Inhibikase Pharmaceuticals, Qwell Pharmaceuticals, New Haven Pharmaceuticals, Alnara Pharmaceuticals, Altus Pharmaceuticals, and Boehringer Ingelheim (BI). While at BI, he oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two FDA Advisory Committee Meetings; and subsequently, all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies. Dr. Blank previously served on the Board of Directors of Riemser Pharma GmbH. Dr. Blank received his medical degree from Universitaet Marburg, Germany. He is board-certified in Germany in internal medicine.
What is the salary of Burkhard Blank?
As the Chief Medical Officer and Head of R&D of Acorda Therapeutics Inc, the total compensation of Burkhard Blank at Acorda Therapeutics Inc is $1,202,610. There are 2 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.
How old is Burkhard Blank?
Burkhard Blank is 65, he's been the Chief Medical Officer and Head of R&D of Acorda Therapeutics Inc since 2019. There are 7 older and 8 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
Insiders trading at Acorda Therapeutics Inc
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith és Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
What does Acorda Therapeutics Inc do?
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
What does Acorda Therapeutics Inc's logo look like?
Complete history of Burkhard Blank stock trades at Acorda Therapeutics Inc és Mannkind Corp
Acorda Therapeutics Inc executives and stock owners
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Ron Cohen,
President,Chief Executive Officer, Director -
Dr. Ron Cohen M.D.,
Founder, CEO, Pres & Director -
Burkhard Blank,
Chief Medical Officer and Head of R&D -
Lauren Sabella,
Chief Commercial Officer -
David Lawrence,
Chief Business Operations, Principal Accounting Officer -
Dr. Burkhard Blank M.D.,
Consultant -
Lauren M. Sabella,
Chief Operating Officer -
Peder Jensen,
Independent Director -
John Kelley,
Non-Executive Independent Chairman of the Board -
Lorin Randall,
Independent Director -
Sandra Panem,
Independent Director -
Barry Greene,
Independent Director -
Catherine Strader,
Independent Director -
Neil S. Belloff Esq.,
Gen. Counsel -
Michael A. Gesser M.B.A.,
Chief Financial Officer -
Dr. Wise Young M.D., Ph.D.,
Special Scientific Advisor -
Kerry M. Clem,
Chief Commercial Officer -
Robert Morales,
Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller -
Peter S. Carbone,
Exec. VP of Quality -
Dr. Andrew R. Blight,
Chief Scientific Officer Emeritus -
Denise J. Duca,
Exec. VP of HR -
Tierney Saccavino,
Exec. VP of Corp. Communications -
Andrew Mayer J.D.,
Sr. VP, Deputy Gen. Counsel & Corp. Sec. -
Felicia Vonella,
VP of Investor Relations -
Ian F Smith,
Director -
Richard P. Batycky,
Chief Tech. Off. & Site Head -
Steven M Rauscher,
Director -
Capital Management Lp Scopi...,
-
Kerry M Clem,
Chief Commercial Officer -
Wise Young,
Director -
Thomas Wessel,
Chief Medical Officer -
Andrew A. Hindman,
Chief Business Dev. Officer -
Barclay A Phillips,
Director -
Capital Investments Ltd.Rid...,
-
Mark R E Pinney,
Director -
Michael Steinmetz,
Director -
Standish Fleming,
Director -
John H Friedman,
Director -
Mary Fisher,
Chief Operating Officer -
Michael W Rogers,
Chief Financial Officer -
Enrique J. Carrazana,
Chief Medical Officer -
Jane Wasman,
President, Intl and GC -
Robert Morales,
Interim PAO & PFO -
John Varian,
Director -
Michael A Gesser,
Chief Financial Officer -
Thomas M. Burns,
Director -
Neil S. Belloff,
General Counsel and Corp Secy